With advances in genetics, direct testing for gene mutations is becoming routine for an increasing number of disorders. These include disorders which in many cases have a common mutational mechanism such as a large deletion (e.g. Duchenne and Becker muscular dystrophy), duplication (e.g. Charcot-Marie-Tooth disease) or expanded trinucleotide repeat (e.g. fragile X, myotonic dystrophy, Huntington's disease, Friedreich's ataxia). In addition, there are several disorders in which one specific mutation is frequent (e.g. cystic fibrosis, Batten's disease).
Direct mutational testing has allowed confirmation of a clinical diagnosis in many patients with these conditions and has also permitted presymptomatic diagnosis for late-onset disorders such as Huntington's disease. In the case of Huntington's many at-risk adults decide not to be tested, in view of the untreatable and progressive nature of the disorder. According to international agreed guidelines1, those who do opt for testing receive detailed counselling beforehand and afterwards.
There has been considerable debate as to whether presymptomatic testing is ethical or appropriate in children. In 1994 a working party of the UK Clinical Genetics Society (CGS) outlined the dilemmas, summarized opinion and practice, and made recommendations2. In response, the British Paediatric Association (BPA) issued a statement in March 1996 that referred specifically to testing of children for adult-onset disease. The BPA declared that predictive testing is appropriate if the condition regularly has its onset in childhood or if a useful medical intervention can be offered (e.g. familial adenomatous polyposis); but formal genetic testing for untreatable adult-onset diseases (such as Huntington's disease) should wait until the 'children' are old enough to request it for themselves.
If testing is requested, the initiative will usually have come from the parents or the medical profession, but occasionally it will be adoption agencies or other third parties. The UK CGS working party consulted 3000-4000 health professionals and the predominant view was that requests for testing should be considered only if they came from the parents or medical advisers.
There has been an increase in requests from young people themselves. How should these be handled?
Discussing requests from adolescents for Huntington's disease (HD) prediction Binedell et al.3 recommend four preliminary steps first, evaluate the person's emotional, cognitive and social maturity; second, ensure that the person is acting autonomously; third, explore the role of the family context in the decision; and fourth, assess the person's experience and confidence in making major personal decisions. In addition, they highlight relevant factors such as how long the adolescent has lived with the knowledge of HD in the family, his or her risk status, and the way that he or she coped with being informed about the risk.
The UK CGS report2 reviewed some of the considerations with regard to testing children at the parents' request. From an ethical viewpoint, testing deprives children of the right to decide for themselves whether or not to be tested as adults. Furthermore, the confidentiality to which an adult is entitled is breached by disclosure of results to the parents; and testing of a child breaches the policy of counselling the person being tested before, during and after the process. Finally, there is concern that a positive test may result in future discrimination by insurers and employers.
Psychologically, there are worries that a positive test may damage a child's self-esteem, distort the family's perceptions of the child or lessen the child's capacity to form relationships. There is some evidence of such illeffects in Huntington's disease4 and within the carrier testing scenario of Tay-Sachs disease5. On the other hand, there can be psychological benefits from allowing the parents to divulge the information over a period of years rather than waiting until adolescence6.
The legal view expressed in the UK CGS report was that a doctor can refuse to test if he or she feels it is not in the child's interests. The difficulty this creates for parents is demonstrated by a small survey conducted by the Genetics Interest Group (GIG), an umbrella organization for lay support groups in the UK, who asked the following question of 34 of their members: 'If testing was refused for ethical reasons, would it be reasonable to consider the use of a private agency?'. 26% said yes, 44% maybe, and 30% no.
What about adoption? The UK CGS working group felt that, in general, there was no indication to test an adopted child any earlier than one would test a child born within a family a view supported by GIG. One possible argument for testing in childhood is that it may obviate the need for arranging follow-up, but there is still the obligation to provide counselling later on. How can this responsibility be discharged? The onus might be transitional to the parents or to the GP, who would be asked to arrange counselling at the appropriate age; but the best (and most expensive) option is to establish genetic family registers, whereby contact is maintained with the family and recall arranged at a suitable time. Computerized recall systems, allied to a strong sense of parental responsibility, make this possible.
PRESYMPTOMATIC TESTING
In view of the above difficulties and uncertainties, can any guidelines be drawn up?
Disorders of childhood onset, with issues of treatment or surveillance Examples here are familial adenomatous polyposis7, hyperlipidaemia8, Marfan's syndrome9 10, adult polycystic kidney disease, neurofibromatosis type 212, von Hippel-Lindau syndrome13, and multiple endocrine neoplasia type 214. If possible, the child should understand why the test is being done.
Even in these circumstances there may be doubt about when to test, and even whether the proposed surveillance or treatment will make a difference. For example, according to a 1994 paper the US National Kidney Foundation recommends that minors should not be tested for adult polycystic kidney disease, even though many paediatricians favour monitoring of blood pressure in children at risk of developing this condition. The authors suggest that, in childhood-onset diseases with childhood interventions, testing need not be performed before the age at which health benefits accrue1 .
A debate on testing of a newborn child for hypertrophic cardiomyopathy was published in the BMJ in 1995. Those in favour argued that a positive result would lead to avoidance of energetic activities and allow regular medical review, with alleviation of symptoms and reduced risk of sudden death16'17. There was also a research indicationi.e. observation of the natural history and studies into prevention although this should only be part of an ethically approved and statistically sensible study. Opponents of testing felt that a positive result could lead to over-protectiveness and do more harm than good. From the parents' viewpoint, Marteau and Michie argued that testing might confer psychological relief from uncertainty18.
The other obvious advantage of testing would be the benefit derived if the test was negative.
Disorders that usually have an adult onset but can present in childhood
There may be a case for testing in some of these. An example is myotonic dystrophy, which can be associated with anaesthetic complications.
Disorders of childhood onset for which there is no specific treatment
In a disorder such as Charcot-Marie-Tooth or a fatal disorder such as Batten's, testing may give parents psychological relief from uncertainty and, in the absence of evidence of harm, their wishes can reasonably be respected. Other benefits might include facilitating open relationships and planning for future housing, schooling, and so on19. All parties must consider the possible ill-effects on a child who may not develop symptoms for many years (e.g. Friedreich's ataxia): will the child be regarded as ill long before symptoms arise? The counter-argument is that the child may be regarded as ill even if he or she is not tested.
WHEN IS TESTING INAPPROPRIATE?
All agree that children should not be tested for adult-onset diseases where there is no treatment.
CARRIER TESTING IN RECESSIVE CONDITIONS AND BALANCED CHROMOSOME REARRANGEMENTS
The UK CGS report judged that carrier testing for recessive disorders and balanced chromosomal rearrangements should be deferred until the child can understand the issues and can request testing in person. Such a policy respects the child's autonomy and avoids the hazard of stigmatization. When questioned, most parents of children attending a cystic fibrosis clinic wanted to know the carrier status of their other children: a large majority felt that the result would not alter the child's upbringing not surprisingly since, being carriers themselves, they should realize that the carrier state is not harmful20. Similarly a retrospective survey of families carrying chromosome translocations showed that most parents thought testing should be offered21. The UK CGS report also warned against inadvertent carrier detection in utero at prenatal diagnosis. In some circumstances this is unavoidable, and the same applies to some neonatal screening programmes e.g. sickle cell disease. Withholding information from parents is not justified but care is required in the delivery of this information so as to avoid stigmatization or psychological sequelae22.
COMMERCIAL TESTING
The arguments indicate the need for detailed counselling and support for families before, during and after testing. Commercial testing of children, without supervision by a genetics centre that has facilities for the necessary counselling, would clearly be inappropriate. The UK Advisory Committee on Genetic Testing is currently examining the whole issue of commercial testing, and its report is eagerly awaited.
TESTING FOR SUSCEPTIBILITY LOCI
Genes that confer susceptibility for complex disorders such as diabetes and coronary artery disease are now being discovered. Tests for such genes should not be offered in the absence of a clear therapeutic indication. CONCLUSION There are now guidelines on when presymptomatic testing in children is appropriate and when inappropriate. Testing carrier status for recessive disorders and balanced chromosomal rearrangements remains a matter of conjecture and further research on the outcome5 is awaited.
When it is deemed appropriate to offer presymptomatic testing or to test a child for carrier status, the paediatrician or geneticist must discuss the pros and cons with the family so that a fully informed decision is reached. Follow-up support and counselling should be available to the families, especially in the event of a positive test result, and a clear arrangement should be made for counselling of the child at appropriate stages in the future. Similarly a follow-up arrangement should be made for those families in which the decision is not to test ideally with a computerized family register. We need research on the psychological impact of the test on child and family, so that future policy can be guided by evidence. Marteau23 comments that any documentation needs to be qualified by the type and amount of counselling provided, as well as the resources of individual families. It will also be necessary to document the consequences of not meeting requests for testing.
